• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
biopharma launch
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs
October 25, 2019 by Global Pricing Innovations (GPI)
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…

October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
Novartis building
October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

September 25, 2019 by Global Pricing Innovations (GPI)
What the Beneluxa Group is aiming for next

BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…

What the Beneluxa Group is aiming for next
June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

June 4, 2019 by Global Pricing Innovations (GPI)
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation.

Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…

May 15, 2019 by Global Pricing Innovations (GPI)
New set of rules regulating medicine prices in Kazakhstan

  New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…

March 4, 2019 by Global Pricing Innovations (GPI)
Employee Spotlight – Popat Bankar

Popat Bankar Business Analyst Joined GPI Mumbai in January 2017 Up this week in our Employee Spotlight Series is our Business Analyst – Popat Bankar. Popat is apart of our fantastic team of analysts based in our office out in Mumbai. Popat sat…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121